| HOME >> BIOLOGY >> TECHNOLOGY |
20102009(unaudited)Cash and investments(1)
$ 231,018$ 162,513Obligations under line of credit
-(37,435)Cash and investments, net of obligations under line of credit(1)
231,018125,078Property and equipment, net
55,40458,754Goodwill
25,79825,798Other intangible assets
53,557-Total assets
370,873257,761Deferred revenue
15,05915,154Current and long-term debt, including line of credit
28,75466,964Noncontrolling interest in Symphony Icon, Inc.
-(290)Accumulated deficit
(650,407)(570,175)Total Lexicon Pharmaceuticals, Inc. stockholders' equity
268,854163,787——————(1) Cash and investments at December 31, 2009 included $5.4 million held by Symphony Icon, Inc. As a result of Lexicon's adoption as of January 1, 2010 of a new accounting pronouncement regarding variable interest entities, the results of Symphony Icon were not consolidated in Lexicon's financial statements for the period from January 1, 2010 through the exercise of the purchase option on July 30, 2010.
'/>"/>
| SOURCE Lexicon Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |